Validation of Ketamine as a Pharmacological Model of Thalamic Dysconnectivity Across the Illness Course of Schizophrenia
Description: Group-level bilateral resting-state thalamic dysconnectivity map derived from healthy volunteers (n = 18) under ketamine relative to placebo. Double-blind, placebo-controlled, crossover design in which participants received intravenous ketamine and placebo (saline) on separate test days.
Citation guidelines
If you use the data from this collection please include the following persistent identifier in the text of your manuscript:
https://identifiers.org/neurovault.collection:12212
This will help to track the use of this data in the literature.
